All results

15 results

• AEVI-007

  The main purpose of the study is to evaluate the safety and tolerability of Camoteskimab in participants with Still's Disease. ### Inclusion Criteria: 1.…

  Ages

  18 Years - 75 Years

  Sexes

  All

• ALXN2050-NEPH-201

  This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study of ALXN2050 (120 and 180 milligrams [mg]) in addition to background therapy…

  Ages

  18 Years - 75 Years

  Sexes

  All

• ATYR

  This randomized, double-blind, placebo matched to efzofitimod-controlled, study will evaluate the safety, tolerability, immunogenicity, pharmacokinetic (PK),…

  Ages

  18 Years - 75 Years

  Sexes

  All

• DREAM

  The overriding objective of DREAM is to conduct a prospective longitudinal (36 months) observational clinical study to investigate the incidence, etiology, and…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Efficacy and Safety of AMG 570 in Subjects With Active SLE

  The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder

  The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular…

  Ages

  18 Years - 75 Years

  Sexes

  All

• First-In-Human Study of Intravenous ATB200 Alone and When Co-Administered With Oral AT2221

  This study is an international, multi-center, study of Pompe disease patients that are currently receiving enzyme-replacement therapy (ERT). The purpose of…

  Ages

  18 Years - 75 Years

  Sexes

  All

• HEAL-IST

  Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality…

  Ages

  18 Years - 75 Years

  Sexes

  All

• Kinect-HD2

  This is a Phase 3, open-label study to evaluate the long-term safety and tolerability of valbenazine, and to provide participants continued access to…

  Ages

  18 Years - 75 Years

  Sexes

  All

• PVT-2201-301

  This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…

  Ages

  18 Years - 75 Years

  Sexes

  All